Lymphoma Canada wishes to thank all of those who particpated in our recent surveys for patients and caregivers.
The survey results have been compiled into Lymphoma Canada’s submissions to the pan Canadian Oncology Drug Review (pCODR) regarding the following indications:
- Bendamustine (Treanda®) for the first line treatment of patients with CLL in combination with rituximab;
- Ibrutinib for the CLL/SLL with or without deletion 17p who have received at least one prior therapy and are not considered appropriate for treatment or re-treatment with a purine analog (e.g., fludarabine);
- Obinutuzuab in combination with chlorambucil for previously untreated chronic lymphocytic leukemia where fludarabine-based therapy is considered inappropriate.
We remain passionate about ensuring that all Canadians have access to the most current and effective treatments for lymphoma. We thank you for your participation in these surveys.
